Blueprint Medicines (BPMC) Tops Q3 EPS by 17c

Blueprint Medicines (NASDAQ: BPMC) reported Q3 EPS of ($0.62), $0.17 better than the analyst estimate of ($0.79). Revenue for the quarter came in at $6.16 million versus the consensus estimate of $6.06 million.

For earnings history and earnings-related data on Blueprint Medicines (BPMC) click here.

You May Also Be Interested In

• FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Green Dot and CommerceOne shareholders approve acquisition deal